Finding infections earlier is only part of the work. At IDWeek 2026, David Weber, MD, MPH, explored how broader surveillance and emerging technologies could help infection preventionists spend more time supporting safer care.
|Articles|September 6, 2016
WHO Issues Updated Guidance on Prevention of Sexual Transmission of Zika Virus
Advertisement
The interim guidance on prevention of sexual transmission of Zika virus has been updated with new evidence and advice. The primary transmission route of Zika virus is via the Aedes mosquito, however mounting evidence shows that sexual transmission of Zika virus is possible and more common than previously assumed. This is of concern due to an association between the Zika virus and adverse pregnancy outcomes.
To read the updated guidance from the World Health Organization (WHO),
Advertisement
Related to this article
Two experts give an update ahead of the first season with a new mRNA vaccine against flu.
Part 1 of 4: How emerging sterile processing leaders are redefining leadership through trust, accountability, psychological safety, and professional development.
This week in infection prevention: Kenya’s Bundibugyo virus response shows why execution, not just planning, determines outcomes, and France reported the first known human Shamonda virus infection. Our roundup also covers brucellosis, blood donor screening, and long-acting HIV antibody findings from IDWeek 2026.
At IDWeek 2026, Jimmy Chang, PhD, discussed investigational HIV antibodies TMB-365 and TMB-380, explaining their complementary mechanisms, early study findings, and ongoing evaluation as a long-acting maintenance regimen.
At IDWeek 2026, Samuel Ntow, MBChB, MPH, discussed research findings of reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.
France’s first reported human Shamonda virus infection raises questions about transmission and vulnerable patients. Explore what investigators know, what remains uncertain, and why infection preventionists should follow this emerging story.
John Rex, MD, CMO of F2G, discusses investigational olorofim’s phase 3 findings, why new antifungals are difficult to develop, and how an oral option could help patients with limited treatment choices.
Advertisement
Advertisement
Trending on Infection Control Today
1
Early Flu, Late RSV: What Infection Preventionists Should Watch This Respiratory Season
2
The Next Generation of SPD Leadership: People First, Standards Always
3
David Weber, MD, at IDWeek 2026: A Career of IPC and His Thoughts on Influential Research
4
ICT Weekly Rounds: Ebola Execution Gaps, a Midge-Borne Virus Jumps to Humans, and IDWeek Findings
5